Oxidative stress contributes to the vascular and neuropathic complications of experimental diabetes mellitus. This is evidenced by measures of tissue oxidant damage such as nerve lipid peroxidation and changes in antioxidant protection systems, for example decreased nerve reduced glutathione (GSH) and superoxide dismutase content [1, 2] . Functional effects of antioxidant treatment include protection of vascular endothelium function [3±5], and improved nerve blood flow, conduction velocity (NCV) and regenerative capacity [2, 6±10]. a-Lipoic acid (LPA) is a naturally occurring free radical scavenger and transition metal chelator. LPA is also a cofactor for mitochondrial pyruvate dehydrogenase and has been termed a ªmetabolic antioxidantº [11] . Recent studies from Low's group [2, 12] showed that treatment with LPA racemate (racLPA) prevented the development of digital sensory NCV deficits, impaired sciatic nerve blood flow, diminished nerve GSH, and deficient glucose uptake by neural tissues in diabetic rats. Short- Diabetologia (1998) Summary Elevated oxidative stress and impaired n-6 essential fatty acid metabolism contribute to defective nerve conduction velocity (NCV) and perfusion in diabetic rats, which may be corrected by free radical scavenger and g-linolenic acid (GLA) treatments. a-Lipoic acid (LPA) has antioxidant actions and both LPA racemate (racLPA) and GLA treatments produced benefits in clinical neuropathy trials. The aims were to study LPA action on neurovascular function in diabetic rats and to investigate potential interactions for co-treatment with GLA and other essential fatty acids. After 6 weeks of diabetes, 2 weeks of racLPA treatment corrected 20 % sciatic motor and 14 % saphenous sensory NCV deficits. The ED 50 for motor NCV restoration was approximately 38 mg kg ±1 day
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. racLPA also corrected a 49 % diabetic deficit in sciatic endoneurial blood flow. R and S-LPA enantiomers were equipotent in correcting NCV and blood flow deficits. Treatment of diabetic rats with low doses (20 mg kg ±1 day ±1 ) of racLPA and GLA, while having modest effects on their own, showed evidence of marked synergistic action in joint treatment, completely correcting motor NCV and blood flow deficits. This was also noted for the novel compound, SOC0150, which contains equimolar proportions of LPA and GLA (ED 50 9.3 mg kg ±1 day ±1 , containing 3.5 mg LPA). NCV effects also showed marked synergism when racLPA:GLA ratios were varied over a 1:3±3:1 range. In contrast, a compound containing LPA and the n-3 component, docosahexaenoic acid, showed similar activity to LPA alone. Thus, LPA-GLA interactions yield drug combinations and compounds with an order of magnitude increase in efficacy against experimental diabetic neuropathy and are worthy of consideration for clinical trials. [Diabetologia (1998) 41 : 390±399] Keywords Neuropathy, nerve conduction, blood flow, essential fatty acid, g-linolenic acid, docosahexaenoic acid, lipoic acid, antioxidant, diabetic rat.
term clinical trials of symptomatic and cardiac autonomic neuropathy showed some beneficial effects of racLPA treatment [13, 14] . R-LPA may be more effective than the S enantiomer in increasing tissue glucose uptake and metabolism and also as an antioxidant [15, 16] , although the latter has been disputed for nervous tissue in vitro [17] . One aim of the investigation was to further characterise LPA effects on NCV and endoneurial blood flow in diabetic rats, including a comparison of R and S enantiomers.
The n-6 essential fatty acid, g-linolenic acid (GLA), prevents and corrects nerve conduction abnormalities in diabetic rats, primarily through improved production of cyclooxygenase-derived vasodilator prostanoids that increase vasa nervorum perfusion [18, 19] . Beneficial GLA effects were found in clinical diabetic neuropathy trials [20] . Previous rat studies revealed synergistic interactions between treatments improving prostanoid synthesis and those correcting nerve function via the vasa nervorum nitric oxide (NO) system, such as aldose reductase inhibitors (ARIs) and antioxidants [21±23] . Thus, a second aim was to assess the effects of joint LPA±GLA treatments both as individual drugs and using a novel compound, SOC0150, GLA-LPA.
Materials and methods
Experiments were performed in accordance with regulations specified in the United Kingdom ªAnimal Procedures Act, 1986º and the National Institutes of Health ªPrinciples of Laboratory Animal Care, 1985 revised versionº.
Experimental groups and diabetes induction. Male SpragueDawley rats (Aberdeen University colony) were used, aged 19 weeks at the start of experiments. Non-diabetic rats were studied at this age as onset controls, to provide a starting value against which to judge any diabetes induced neuropathic deterioration. In this mature rat model, there is no significant difference between NCV or blood flow values in onset and agematched control groups [24±26]. Diabetes was induced by streptozotocin (Zeneca, Macclesfield, Cheshire, UK) freshly made up in sterile 154 mmol l ±1 NaCl solution, at a dose of 40±45 mg kg ±1 i. p. Diabetes was verified after 24 h by the presence of hyperglycaemia and glucosuria (Visidex II and Diastix; Ames, Slough, UK) in non-fasted rats. After final experiments, plasma glucose was estimated (GOD-Perid method; Boehringer Mannheim, Mannheim, Germany) on samples taken from a carotid artery cannula or the tail vein. Diabetes duration was 8 weeks and, where appropriate, treatment was given for the last 2 weeks.
There were two sets of investigations. In the first, the efficacy of LPA racemate (racLPA) for correcting proximal sciatic motor NCV deficits was estimated at doses of 20, 50 and 100 mg kg ±1 day
±1
. For the highest dose, effects on sciatic endoneurial blood flow and saphenous sensory NCV were also measured. Finally, the effects of R and S enantiomers were compared at a dose of 40 mg kg ±1 day
, which approximates the EC 50 for racLPA.
The second set of experiments examined the effects of low doses of racLPA (20 mg kg ±1 day
) and GLA ethyl monoester
, supplying 20 mg kg ±1 day ±1 GLA), alone and as a joint treatment to examine potential synergistic interactions for blood flow and NCV. Further experiments studied the effects of SOC0150, 1-(z,z,z-octadeca-6,9,12-trienoic acid)-3-(DL-1,2-dithiolane-3-pentanoic acid)-propyl diester, a novel compound containing equimolar amounts of GLA and LPA, to establish dose-response relations for NCV and to examine the effects of high dose treatment on endoneurial blood flow. Additional neurovascular measurements were made on a mixture of pure GLA and racLPA containing the equimolar proportions found in SOC0150. The effects of varying the LPA:GLA ratio on NCV were studied using racLPA and GLA monoester. Finally, to test whether essential fatty acid ± LPA synergistic interactions extended to the n-3 series, the effects of treatment with the novel compound, docosahexaenoic acid (DHA)-LPA were examined for NCV.
LPA (ASTA Medica, Frankfurt, Germany) powder was mixed with sterile saline and NaOH was added until the suspension dissolved. The pH was then brought to 7.4 with HCl. The LPA solution was given by daily i. p. injection. For the interaction experiments, GLA, as the monoester or pure GLA (Scotia Pharmaceuticals, Stirling, UK) was given as a dietary supplement, dispersion of the appropriate dose of oil being aided by the addition of 9 ml of sunflower oil in 1.5 kg of diet. Previous experiments have shown that this or higher levels of sunflower or corn oil (both contain 70 % linoleic acid and were given at up to a 10 % dietary supplement) treatment have no effect on NCV or blood flow in diabetic and nondiabetic rats [24, 26] . For experiments on the effects of SOC0150 (Scotia Pharmaceuticals), which contains 38.5 % w/w LPA and 49.8 % w/w GLA, treatment was given as a dietary supplement with sunflower oil to aid dispersion as described above. In this case, comparison was made with a mixture of pure GLA and racLPA dispersed in sunflower oil and added to the diet. The DHA-LPA compound (Scotia Pharmaceuticals) was similarly dispersed in the diet with sunflower oil.
Nerve conduction velocity. At the end of the treatment period, rats were anaesthetised with thiobutabarbital (Zeneca) by intraperitoneal injection (50±100 mg kg ±1 ). The trachea was cannulated for artificial ventilation and a carotid cannula was used to monitor mean systemic blood pressure. Motor NCV was measured between sciatic notch and knee in the nerve branch to tibialis anterior muscle, which is representative of the whole sciatic nerve in terms of susceptibility to diabetes and treatment effects [24, 25] . Saphenous sensory NCV was measured between groin and ankle as previously described [25] . Rectal and nerve temperatures were monitored, and regulated between 36.5 and 37.5°C.
Nerve blood flow. Sciatic endoneurial blood flow was measured by microelectrode polarography and hydrogen clearance as previously described [6, 21, 26] . Briefly, rats were given neuromuscular blockade using d-tubocurarine (Sigma, 2 mg´kg ±1 via the carotid cannula) and were artificially ventilated. The level of anaesthesia was monitored by observing any reaction of blood pressure to manipulation, and supplementary thiobutabarbitone was given as necessary. Body core temperature was maintained at 37±38°C and nerve temperature was controlled within the range 35±37°C by radiant heat applied to a pre-warmed mineral oil pool that bathed the exposed sciatic nerve. A glass-insulated H 2 -sensitive electrode was inserted into the middle of the nerve. 10 % H 2 was added to the inspired gas, the proportions of O 2 and N 2 being adjusted to 20 % and 70 %, respectively. When the electrode H 2 current had stabilised, the H 2 supply was shut off and the clearance monitored. This was repeated at another nerve site. Mono-or bi-exponen-tial curves were fitted to the data by regression analysis (Prism; Graphpad, San Diego, Calif., USA). The slow exponent was taken to reflect nutritive capillary flow [27] . Vascular conductance was calculated by dividing blood flow by mean arterial blood pressure. Endoneurial perfusion parameters were averaged from the two clearance measurements.
Statistical analysis. Data are expressed as mean ± SEM. They were first subjected to Bartlett's test for homogeneity of variances and were given a log transformation if necessary (all blood flow and vascular conductance data for the interaction studies). One-way analysis of variance was then performed, followed by the Student-Newman-Keuls test to estimate the significance of differences for individual between-group comparisons. Where log transformation failed to equalize group variances (blood pressure, LPA study) the non-parametric Kruskal-Wallis analysis of variance was used, followed by Dunn's multiple comparison test. For the interaction study, differences between observed and predicted treatment effects were analysed using one sample Student's t-tests. A value of p less than 0.05 was considered statistically significant. Sigmoid dose-response curves were constructed using the Marquardt algorithm and the least squares method for optimizing goodness-of-fit, using commercial software (Prism).
Results
Effects of a-lipoic acid racemate treatment on nerve conduction velocity and sciatic endoneurial blood flow in diabetic rats. Data for body weights and plasma glucose concentration are given in Table 1 . Eight weeks of diabetes caused an approximate 30 % reduction in body weight and plasma glucose was elevated approximately 7-fold. This was not affected by LPA treatment for the final 2 weeks.
NCVs for sciatic motor fibres to tibialis anterior muscle ( Fig. 1A ) and saphenous sensory fibres (Fig. 1B) were reduced by 8 weeks of diabetes to the extent of 20.2 ± 0.7 % (p < 0.001) and 13.9 ± 0.7 % (p < 0.001), respectively. Treatment with 100 mg kg ±1 day ±1 racLPA for the last 2 weeks corrected the motor NCV deficit by 88.2 ± 4.4 % (p < 0.001) although the remaining small deficit was statistically significant (p < 0.05) compared to the non-diabetic group. Saphenous sensory NCV was completely corrected (p < 0.001) by racLPA.
Sciatic endoneurial blood flow ( Fig. 2A ), 48.6 ± 2.9 % reduced (p < 0.001) by diabetes, was largely (78.7 ± 9.4 %; p < 0.001) corrected by racLPA (100 mg kg ±1 day ±1 ) treatment, the resultant value being within the non-diabetic range. Compared to the non-diabetic group, mean systemic blood pressure ( Fig. 2B ) tended to be reduced (~18 %) in both diabetic control (p < 0.05) and racLPA-treated groups (p < 0.01). Because vasa nervorum has poor or absent pressure autoregulation [27] , such pressure variations would influence blood flow. To take pressure into account, the flow data are expressed as nutritive vascular conductance in Figure 2C . This was 41.4 ± 3.6 % (p < 0.001) reduced by diabetes, the deficit being completely corrected (p < 0.001) by racLPA treatment. Data are mean ± SEM ) for both R-and S-LPA, significantly improved compared to untreated diabetes (p < 0.001) but reduced compared to the non-diabetic control group (p < 0.001). The degree of NCV correction was similar to expectations from the racLPA dose-response curve for both R-and S-LPA. Interaction between a-lipoic acid and g-linolenic acid treatments, the effects of SOC0150, and a compound containing a-lipoic acid and the n-3 component, docosahexaenoic acid. Eight weeks of diabetes caused hyperglycaemia and an approximate 25 % reduction in body weight (Table 2) , which were not affected by treatment during the final 2 weeks.
There was a 19.7 ± 0.8 % (p < 0.001) deficit in sciatic motor NCV after 8 weeks of diabetes (Fig. 4) . This was partially corrected by low dose (20 mg kg ±1 day ±1 i. p.) racLPA (21.6 ± 4.0 %; p < 0.01) or low dose (20 mg kg ±1 day ±1 p. o.) GLA monoester (18.7 ± 3.8 %; p < 0.01) treatments alone over the last 2 weeks. However, in diabetic rats given joint racLPA-GLA monoester treatment, the degree of NCV correction was 93.2 ± 4.1 % (p < 0.001), the resultant value being in the non-diabetic range. The predicted NCV value for the joint treatment group was 55.7 m s ±1 on the assumption of additivity of drug effects. The observed value of 62.9 ± 0.5 m s ±1 substantially exceeded this prediction (p < 0.0001), 
±1
, n = 7±10; R40 and S40 6 week diabetic rats treated for a further 2 weeks with R or S enantiomers of a-lipoic acid at a dose of 40 mg kg ±1 day ±1 , n = 10. Data are mean ± SEM. Upper and lower sets of dashed lines represent the envelope of mean ± SEM of representative non-diabetic and diabetic control groups respectively, from data in Figure  1 . Statistics: R40 vs S40, NS; R40 or S40 vs LPA50, NS; R40 or S40 vs LPA20 or LPA100, p < 0.001; R40, S40, LPA20, LPA50 or LPA100 vs diabetic control group, p < 0.001; R40, S40, LPA20 or LPA50 vs non-diabetic group, p < 0.001; LPA100 vs non-diabetic group, p < 0.05 indicating a synergistic interaction between the two treatments. Figure 4 also shows the effects of dietary supplementation with a dose of 48 mg kg ±1 day ±1 SOC0150, (which would give doses of 23.4 mg kg ±1 day ±1 GLA and 18.1 mg kg ±1 day ±1 LPA on complete hydrolysis of the ester), and joint treatment with the same amounts of pure GLA and racLPA by dietary supplementation. These treatments corrected NCV by 98.7 ± 6.4 % (p < 0.001) and 93.1 ± 6.0 % (p < 0.001), respectively; the resultant values were not significantly different from each other or from the NCV value for the non-diabetic group. Based on a consideration of the NCV dose-response curves for GLA [19, 23] and racLPA, the predicted NCV value for additive effects between the two components was 56.0 m s ±1 . This was substantially exceeded with SOC0150 (p < 0.0001) and the corresponding GLA-racLPA treatments (p < 0.0001) indicating synergistic interactions. NCV was also examined in two further groups (n = 6±8) of SOC0150 treated diabetic rats at doses of 5 and 16 mg kg ±1 day ±1 to enable the dose-response curve to be estimated. This is shown in Figure 4B , in terms of LPA content, for comparison with the racLPA dose-response relationship. The log EC 50 for SOC0150 was 0.968 ± 0.046, corresponding to a dose of approximately 9.3 mg kg ±1 day ±1 (which would give~3.5 mg kg ±1 day ±1 LPA and~4.5 mg kg ±1 day ±1 GLA). Figure 4B also shows data for a group of diabetic rats (n = 8) treated with DHA-LPA, at a dose of 50.4 mg kg ±1 day ±1 (which, when hydrolysed would yield 18.1 mg kg ±1 day ±1 LPA and 27.4 mg kg ±1 day ±1 DHA). NCV was 54.0 ± 0.4 m s ±1 , which did not differ significantly from the 53.3 m s ±1 predicted from the racLPA dose-response curve for the LPA component alone.
Sciatic nutritive endoneurial blood flow (Fig. 5A ), 48.4 ± 2.4 % reduced by 8 weeks of diabetes, was not significantly affected by racLPA (41.8 ± 5.1 % deficit) or GLA (41.7 ± 2.7 % deficit) treatment alone. However, for joint racLPA-GLA treatment, flow was in the non-diabetic range, significantly elevated compared to diabetic control and single treatment groups (p < 0.001). This was also noted for the SOC0150-treated group and rats treated jointly with comparable doses of pure GLA and racLPA.
Compared to the non-diabetic group, mean systemic blood pressure (Fig. 5B ) tended to be reduced (~14 %) by diabetes regardless of treatment and this was statistically significant for diabetic control, racLPA and GLA-treated groups (p < 0.05). Nutritive endoneurial vascular conductance (Fig. 5C ) was 39.6 ± 2.2 % (p < 0.001) reduced by diabetes, not significantly altered by racLPA or GLA treatments alone, but completely corrected by joint racLPA-GLA treatment (p < 0.001). A similar correction of vascular conductance was observed using SOC0150, and pure GLA with racLPA cotreatment (both p < 0.001 vs diabetic control group, NS vs the non-diabetic group). For nutritive blood flow and vascular conductance, the magnitude of the joint GLAracLPA treatment increment exceeded additivity predictions by 3.7-fold (p = 0.004) and 3.3-fold (p = 0.012), respectively, indicating a synergistic interaction for nutritive perfusion.
NCV results from an experiment examining lower dose GLA ± racLPA mixtures and ratiometric effects are shown in Table 3 . A mixture of 6.7 mg kg ±1 day ±1 racLPA given by daily i. p. injection and 6.7 mg kg ±1 day ±1 GLA as the monoester, gave an NCV that far exceeded the expected value for additivity. Based on dose-response curves for GLA and racLPA, the excess NCV above the expected value could be produced by an average 6-fold increase in GLA or racLPA dose. Treatment with racLPA ± GLA monoester mixtures in 3:1 and 1:3 ratios were also examined (Table 3) . In both cases, whether racLPA or GLA was predominant, observed motor NCV exceeded additive predictions, indicating a substantial synergy between the treatments. When racLPA was in relative excess, the synergistic effect was equivalent to an average 3.8-fold increase in racLPA or GLA dose whereas when GLA was predominant the equivalence was for a 5.1-fold increased dose. Data are mean ± SEM a Doses matched for comparison with SOC0150
Discussion
The data show that racLPA is effective in correcting NCV and nerve perfusion abnormalities in diabetic rats. This provides additional information to complement a previous racLPA study by Nagamatsu et al. [2] , which used a preventive design over 1±3 months of diabetes. However, there are some differences in the NCV findings. While that study showed dose-dependent protection of hind limb digital sensory NCV, motor NCV in sciatic tibial-interosseous and caudal nerves was not significantly altered. However, in their model, diabetes was induced in young (8 weeks of age) rats and part of the NCV deficit depends on blunting of the axial growth and maturation of nerve fibres [28, 29] so that motor NCV deficits are relative to age-matched rather than onset control values. In contrast, in our mature rat model using proximal sciatic nerve fibres, motor NCV changes are relative to onset controls and there is little further maturation effect [24, 25] . The sciatic tibial-interosseous preparation is also more resistant to diabetes than the proximal sciatic branches [24, 30] , and may be day ±1 g-linolenic acid to mimic SOC0150 treatment (SOM, n = 9). The horizontal dashed line in A shows the expected conduction velocity level for combined treatment in the GL group, calculated from LPA and G group data assuming additivity of effects. B shows the dose response relationship for SOC0150 (U, n = 7±10) and the best fit sigmoid (solid curve). The dose response relationship for a-lipoic acid racemate is given for comparison (dashed curve). Conduction velocity data for docosahexaenoic acid ± lipoic acid (A, n = 8) at a daily dose of 50.4 mg kg ±1 day
±1
. Upper and lower sets of dashed lines represent the envelope of mean ± SEM of representative non-diabetic and diabetic control groups respectively, from data in Figure 4A . Data are mean ± SEM. Statistical analysis: motor conduction velocity, D vs LPA and G, p < 0.01; D vs all other groups, p < 0.001; G or LPA vs N, GL, SOC or SOM, p < 0.001; all other comparisons NS less amenable to some treatments such as aldose reductase inhibitors [25] . A similar discrepancy between maturation effects and different nerve branches was noted for aminoguanidine treatment. Thus, effects on sciatic tibial-interosseous nerve in young diabetic rats were delayed until 4 months of aminoguanidine treatment [31] . However, in proximal sciatic motor nerves, aminoguanidine prevented and rapidly reversed NCV deficits in mature diabetic rats [32] . Thus, it is plausible that discrepant observations of racLPA effects on motor NCV reflect the nerve branch studied, the duration of treatment and the age at which diabetes was induced. Nonetheless, the data clearly show that racLPA corrects motor and sensory NCV defects, as do several other antioxidants including vitamin E, probucol and acetyl cysteine [6, 7, 9, 10] .
racLPA corrected sciatic endoneurial blood flow deficits in a dose-dependent manner, 100 mg kg ±1 day ±1 causing complete normalisation whereas 20 mg kg ±1 day ±1 had a minimal effect. This is in good agreement with the relationship described by Nagamatsu et al. [2] . In that preventive study, racLPA did not alter blood flow and NCV in non-diabetic rats, which concurs with data for other antioxidants [6, 8, 9] . Rand S-LPA enantiomers were equipotent in correcting NCV and blood flow deficits, the results fitting well with predictions from the dose-response curve for racLPA. R-LPA has been reported to be much more effective than S-LPA in increasing tissue glucose uptake and metabolism [15] . In diabetic rat sciatic nerve, racLPA treatment increased glucose uptake to compensate for a deficit in this parameter [12] , presumably due mainly to the R-LPA component. The similarity of R-LPA and S-LPA actions in this investigation suggests that beneficial effects on nerve function do not depend upon promotion of glucose uptake under the conditions of these experiments; nerve glucose is already approximately 10-fold elevated in our hyperglycaemic rat model [33] . However, under hypoglycaemic conditions, for example with intensive insulin treatment, LPA-dependent improvements in nerve glucose homeostasis might prevent the fibre degeneration characteristic of that state [34] . Arguably, a potential disadvantage of increased glucose uptake, coupled with hyperglycaemia, would be a further elevation in sciatic nerve polyol levels. Although not measured in this study, it was previously found that 100 mg kg ±1 day ±1 racLPA treatment doubled nerve sorbitol content in diabetic rats [12] . However, the 3±11-fold sorbitol increases in diabetic and nondiabetic rats treated with a sorbitol dehydrogenase inhibitor did not have any adverse effects on NCV [33] , suggesting that polyol accumulation is relatively unimportant.
LPA scavenges hydroxyl radicals, hyperchlorous acid, hydrogen peroxide, singlet oxygen and peroxynitrite, but not superoxide radicals. LPA also chelates transition metals, thus reducing free radical formation by glucose autoxidation and hydroxyl radical production by the Fenton reaction. Tissues can convert LPA to dihydro-LPA, which, although ineffective against singlet oxygen, has a broader spectrum of action than LPA, additionally scavenging superoxide and peroxyl radicals [11] . R-and S-LPA enantiomers are converted to dihydro-LPA by different routes; R-LPA is metabolised by dihydrolipoamide dehydrogenase in mitochondria, which requires NADH as cofactor. S-LPA is converted in the cytosol and mitochondrial matrix by glutathione reductase, which requires NADPH [11] . The LPA-dihydro-LPA cycle may recycle major antioxidants including glutathione, ascorbate, thioredoxin and ubiquinone. In turn, these participate in vitamin E regeneration from its oxidised radical [11] , although this LPA effect has been disputed in vivo under conditions of vitamin E deficiency [35] .
Conversion to dihydro-LPA may be important for LPA action because neutralisation of the endothelial vasodilator, NO, by superoxide contributes to reduced vasa nervorum blood flow in diabetic rats [4, 6, 21, 36±38] . Given that R and S-LPA are metabolised to dihydro-LPA by different pathways, the potential effect of diabetes requires consideration. Nerve mitochondrial NADH/NAD + ratio is increased by diabetes [39] , as expected for endoneurial hypoxia [27, 40] . This would favour the conversion of R-LPA to dihydro-LPA. However, the improvement in vasa nervorum blood flow by LPA would restore mitochondrial NADH/NAD + , as noted for vasodilator [39, 40] , thereby negating this advantage. Synthesis of sorbitol from glucose by aldose reductase limits NADPH availability for glutathione reductase, which causes an ARI-correctable reduction in nerve GSH content in diabetes [41] . An NADPH deficit would impair dihydro-LPA production from S-LPA. Against that, however, the direct effect of LPA in recycling oxidised glutathione would bypass glutathione reductase; the diminished nerve GSH content in diabetic rats is prevented by racLPA treatment [2] . Thus, more enzyme and NADPH would be available for S-LPA to dihydro-LPA conversion. A ªNADPH-sparingº effect of LPA could also benefit vasa nervorum endothelial function because NAD-PH is a cofactor for NO synthase. racLPA treatment protects against defective corpus cavernosum NOmediated relaxation involving both vascular endothelium and nitrergic nerves in diabetic rats [42] . Thus, LPA effects are likely to be more complex than anticipated for a simple free radical scavenger, and beneficial actions of both R-and S-LPA on diabetic nerve function would be expected, in line with the observations.
The synergistic interaction between LPA and GLA in correcting NCV and blood flow deficits, whether given separately or combined as a novel compound, SOC0150, concurs with predictions from previous work. Thus, combined cyclooxygenase and NO synthase inhibitor treatment produced NCV defects in non-diabetic rats similar to those found in diabetes, and there was a substantial synergy between those drugs [43] . The interpretation was that cyclooxygenase inhibition reduced the synthesis of prostacyclin whereas NO synthase inhibition impaired vasodilation by NO, joint treatment disrupting the normal compensatory interactions between these complimentary endothelial vasodilator systems. The consequences of the diabetic deficit in the vasa nervorum NO system [36, 37] are greatly exacerbated by impaired prostacyclin synthesis [44] , primarily due to reduced availability of arachidonic acid consequent to defective D-6 desaturation of linoleic acid. This may be restored by GLA or arachidonic acid treatment [19, 40, 45] . Thus, joint treatment of diabetic rats with drugs targeting the prostacyclin (GLA) and vascular NO system (antioxidants and ARIs) [3±5, 40, 41, 46] might be expected to show mutual facilitation. This was seen for nerve blood flow and NCV using a combination of GLA-rich evening primrose oil and aldose reductase inhibitors [21] , GLA and a probucol analogue [22] and the novel drug, ascorbyl-GLA [23] . Because of LPA's neurovascular and NO system actions [2, 42] it was considered a good candidate for investigating potential interactions with GLA treatment. The degree of synergism between LPA and GLA was high, resulting in a drug mixture or the compound SOC0150 that had a several-fold increase in efficacy for correcting motor NCV and endoneurial blood flow defects. Experiments using different molar ratios of LPA and GLA showed that a synergistic interaction was present over a wide range of relative concentrations from 3:1 in favour of LPA to 3:1 in favour of GLA. However, the interaction was greatest when ratios were roughly equal or with GLA somewhat in excess. Thus, the 1.3:1 GLA:LPA ratio for SOC0150 is likely to be reasonably optimal.
Comparison of the effects of SOC0150 with that of DHA-LPA at a dose that contained the same LPA content, showed that DHA-LPA had a much lesser effect, not significantly better than that expected for LPA alone. DHA (22:6n-3) is an n-3 essential fatty acid metabolite, one elongation and desaturation step downstream of eicosapentaenoic acid 20:5n-3 (which is the n-3 homologue of arachidonic acid 20:4n-6). DHA is found in high concentrations at synaptic junctions and in the brain and is essential for the development and function of retina and brain [47] . DHA has vascular actions, including inhibition of cyclooxygenase-mediated prostanoid production from arachidonic acid which would reduce nerve blood flow; however, lipoxygenase products of DHA inhibit thromboxane A 2 effects on platelets and vascular smooth muscle, which would tend to improve perfusion [40, 45, 48] . Thus, although DHA is important for structure and function of neural membranes, vascular effects are likely to be relatively neutral. This would explain the lack of interaction with LPA for NCV and contrasts with LPA-GLA mixtures and SOC0150 where GLA, via conversion to arachidonic acid, is a precursor of vasodilator prostanoids such as prostacyclin that increase nerve perfusion [40] .
In conclusion, the data show an enantiomer-independent beneficial action of LPA on blood flow and NCV in diabetic rats. Furthermore, facilitatory interactions with joint GLA treatment greatly amplified these advantageous effects. Given that LPA and GLA both showed some benefits in clinical trials [13, 20] , joint or SOC0150 treatment would be a logical elaboration offering enhanced efficacy.
